Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients: Impact of CYP3A5 Genotype on Starting Dose.
- Bergman, Troels K.
- Hennig, Stefanie
- Barraclough, Katherine A.
- Isbe,l Nicole M.
- Staatz, Christine E.
Publication date
January 2013
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
Objectives: The aims of this study were to develop a population pharmacokinetic model of tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome P450 3A5 (CYP3A5) genotype-based initial dosing of tacrolimus with standard per-kilogram-based dosing, and to predict the best starting dose of tacrolimus based on patient genotype to achieve a trough concentration between 6 and 10 mu g/L by day 5 posttransplantation
Add to ORKG